Please login to the form below

Not currently logged in
Email:
Password:

EpiCept's Ceplene NDA rejected

The US Food and Drug Administration has refused a New Drug Application for EpiCept Corporation's Ceplene, a treatment for acute myeloid leukaemia

The US Food and Drug Administration (FDA) has refused to accept for filing EpiCept Corporation's New Drug Application (NDA) for Ceplene (histamine dihydrochloride), the company's experimental treatment for acute myeloid leukaemia (AML). The federal agency recommended that EpiCept conduct an additional pivotal trial before resubmitting the application.

Ceplene, which EpiCept is developing for AML remission maintenance and the prevention of relapse in patients in first remission, is intended to be co-administered with low-dose interleukin-2 (IL-2). According to the FDA, a preliminary review of the Ceplene NDA did not establish Ceplene's therapeutic contribution in the drug combination.

The agency recommended that EpiCept conduct a confirmatory pivotal trial assessing Ceplene's contribution, using overall survival as a primary endpoint, before resubmitting the NDA. EpiCept said it intends to request a meeting with the FDA as soon as possible to discuss whether it will be possible to resubmit the application without conducting another clinical trial. The company also noted that it has the right to file the marketing application even over the FDA's objections.

The NDA already contains a phase III study that demonstrates that the drug combination provided a statistically significant improvement in leukaemia-free survival without impacting patients' quality of life. It also contains the results of two meta-analyses designed to help isolate Ceplene's efficacy, which were included at the FDA's request.
The first meta-analysis confirmed the lack of clinical efficacy of IL-2 monotherapy for the indication, while the second demonstrated Ceplene's contribution, according to EpiCept.

EpiCept president and CEO Jack Talley said he was "surprised and obviously very disappointed" by the FDA's refusal to file the application. Ceplene is EpiCept's lead drug candidate, although the company also has a prescription topical analgesic cream in late-stage clinical development for long-term relief of pain associated with peripheral neuropathies, as well as two oncology drug candidates also in clinical trials.

EpiCept submitted the Ceplene NDA in late June and requested a priority review, meaning that the company had hoped to receive a decision from the FDA by December of this year.

Ceplene was approved in the European Union in 2008. Marketing applications for the drug are currently under review in Canada and Israel.

24th August 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics